MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development

  • Authors:
    • John M. Yavorski
    • George Blanck
  • View Affiliations

  • Published online on: September 29, 2017     https://doi.org/10.3892/mco.2017.1432
  • Pages:1119-1121
Metrics: PDF 0 views | HTML 0 views
0

Abstract

The role of tumor cell expression of major histocompatibility class II (MHCII) has been controversial, with evidence indicating that tumor cell expression of MHCII may lead to an anti‑tumor immune response and to tumor cell apoptosis and that MHCII has pro‑tumorigenic functions. The cancer genome atlas (TCGA) indicates numerous deleterious mutations for the highly specific, MHCII transcriptional activation proteins, RFX5, RFXAP, RFXANK and CIITA. Also, mutations in the non‑polymorphic, human leukocyte antigen (HLA)‑DRA gene, which encodes the heavy chain for the most prominent human MHCII molecule, HLA‑DR, are common. For many, if not most TCGA cancer datasets, the MHCII specific mutations do not associate with clinical outcomes. However, stomach carcinoma represents an exception, where the data indicate that MHCII‑specific mutations are associated with a more favorable outcome. These data raise the question of whether stomach cancer mutations represent effective haploinsufficiency or whether mutations that are associated with a favorable outcome occur with other stomach cancer molecular features that limit the function of the two alleles that represent these MHCII‑related proteins.

Related Articles

Journal Cover

December 2017
Volume 7 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yavorski, J.M., & Yavorski, J.M. (2017). MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development. Molecular and Clinical Oncology, 7, 1119-1121. https://doi.org/10.3892/mco.2017.1432
MLA
Yavorski, J. M., Blanck, G."MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development". Molecular and Clinical Oncology 7.6 (2017): 1119-1121.
Chicago
Yavorski, J. M., Blanck, G."MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development". Molecular and Clinical Oncology 7, no. 6 (2017): 1119-1121. https://doi.org/10.3892/mco.2017.1432